Oral Cancer Screening

ViziLite Plus

The newest tool now available in our office in the fight against oral disease is the ViziLite Plus oral lesion identification and marking system. Vizilite Plus, from Zila Pharmaceuticals, combines the oral screening technology of Vizilite, an advanced chemiluminescent light technology to help detect oral abnormalities, with TBlue630T. TBlue630T is the only patented pharmaceutical-grade form of toluidine blue that has been cleared by the FDA for use in marking lesions identified during a ViziLite examination.

ViziLite Plus makes oral screening more comprehensive than ever before and is indicated for the use in individuals at increased risk of oral cancer. If Vizilite reveals an abnormality, TBlue630 can be used to mark more suspicious lesions for further evaluation.

How ViziLite Plus Works

As with most serious diseases, early detection is the key to successful outcomes. Unfortunately, the problem with oral cancer is that approximately 70% of the time it is not visible to the dental professional until it has reached an advanced stage. ViziLite Plus technology assists us in seeing abnormal tissue in the mouth, before it is plainly obvious.

As ViziLite Plus passes over oral tissue that has been treated with the rinse solution, normal healthy tissue will absorb the light and appear dark, abnormal tissue will appear white. The purpose of using ViziLite Plus is to identify tissue changes at their earliest stage; once abnormal tissue has been identified it is up to Dr. Belenski or Dr. Bock to determine what the appropriate next steps are.